Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310221 | 0.80 | PDE5A (0.32) | CA14 | |
| SCHEMBL1950353 | 0.77 | HDAC6 (0.35) | CA14HDAC6HDAC1HDAC2CNR2 | |
| SCHEMBL4758704 | 0.76 | HDAC6 (0.34) | CA14MAOAMAOBHDAC6HDAC1 | |
| SCHEMBL7465609 | 0.75 | CCR3 (0.34) | TDP1HDAC1HDAC2CNR2 | |
| SCHEMBL28793329 | 0.75 | TDP1 (0.43) | TDP1CA14MAOAMAOBHDAC6 | |
| SCHEMBL7455821 | 0.74 | KDM1A (0.35) | TDP1HDAC6CNR2 | |
| SCHEMBL7468456 | 0.74 | CCR3 (0.35) | CNR2 | |
| SCHEMBL28329436 | 0.72 | EPHX1 (0.40) | TDP1CA14MAOAMAOBHDAC6 | |
| SCHEMBL4693101 | 0.69 | HDAC6 (0.39) | CA14HDAC6HDAC1HDAC2CTSK | |
| SCHEMBL111602 | 0.69 | CA14 (0.40) | CA14HDAC6HDAC1HDAC2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2250164-A2 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | Nicox S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-2125695-A2 | NITRIC OXIDE DONOR COMPOUNDS | Nicox S.A. (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009106471-A2 | NEW ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | NICOX S.A. (FR) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | TDP1 2780/4885CA14 4463/4885MAOA 478/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | TDP1 2698/4885CA14 4469/4885MAOA 562/4885 |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | AGTR1, AGTR2, AGT | TDP1 4548/4885CA14 4693/4885MAOA 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.